CIK 0001563880
- Non-accelerated filer
- Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 450834299
- Phone
- +1 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Exercise or conversion Chief Financial Officer acquired 6,000 shares (option exercise)
- 4 Exercise or conversion Galletta Christopher acquired 15,000 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale President & CEO sold 6,059 shares at an average $3.03 ($18,371)
- 4 Open-market sale President & CEO sold 55,121 shares at an average $3.09 ($170,193)
- 4 Open-market sale Director sold 4,555 shares at $2.93 ($13,353)
- 4 Open-market sale Chief Scientific Officer sold 16,496 shares at $2.96 ($48,883)
- 4 Open-market sale Chief Scientific Officer sold 31,505 shares at an average $2.77 ($87,228)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Scientific Officer sold 53,368 shares at $2.55 ($136,110)
Page 3 of 13 · 257 filings